Curaleaf has appointed Torsten Greif to the Curaleaf Board of Directors.
Mr. Greif is a respected entrepreneur and one of the founders of Four 20 Pharma GmbH, Curaleaf's flagship German brand. With deep expertise in cannabis cultivation, regulatory strategy, and brand development, he has been instrumental in positioning Four 20 Pharma as a leading premium cannabis provider in Germany's emerging medical cannabis market. Under his leadership, the company achieved a majority stake sale to Curaleaf, underscoring his strategic vision, cross-industry approach, and ability to find success in the evolving German cannabis market.
© Curaleaf
"We're thrilled to welcome Torsten to the global Curaleaf leadership team," said Boris Jordan, Chairman and Chief Executive Officer of Curaleaf. "Torsten's vision, deep local knowledge, and proven ability to execute in complex regulatory environments will be tremendous assets as we continue to scale Curaleaf's European operations. His leadership reflects our commitment to building best-in-class cannabis businesses around the world."
"I'm honored to join Curaleaf at this important stage of the company's international expansion," said Mr. Greif. "The European cannabis market is evolving rapidly, and I look forward to partnering with our talented teams to deliver high-quality, EU-GMP-certified medical cannabis to Germany and beyond. Curaleaf's global platform will enable us to accelerate innovation and contribute to the broader legitimization of cannabis in Europe."
For more information:
Curaleaf
[email protected]
curaleaf.com
